Seda Badalyan, MD
Internal Medicine · la Jolla, CANPI 1558396077
Payments from drug & device makers
Across 234 payments — averaging $21.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- Lilly USA, LLC$712
- AbbVie$398
- Novo Nordisk$398
- Pfizer$371
- Amgen$364
- plus $2K from 21 others
What the payments were for
- Food & beverage$5,08199%
- Education$501%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 49 | $1,140 |
| Lilly USA, LLC | 30 | $712 |
| AbbVie | 16 | $398 |
| Novo Nordisk | 19 | $398 |
| Pfizer | 14 | $371 |
| Amgen | 18 | $364 |
| GSK | 16 | $313 |
| Currax Pharmaceuticals LLC | 21 | $299 |
| Hologic Sales And Service, LLC | 2 | $143 |
| Exact Sciences | 7 | $142 |
| Novartis | 7 | $127 |
| Astellas Pharma US Inc | 5 | $113 |
| Esperion Therapeutics, Inc. | 5 | $97 |
| Otsuka America Pharmaceutical, Inc. | 3 | $72 |
| Idorsia Pharmaceuticals US Inc | 4 | $68 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $65 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $55 |
| Daiichi Sankyo Inc. | 2 | $41 |
| Sumitomo Pharma America, Inc. | 2 | $37 |
| Cequr Corporation | 1 | $36 |
| Boehringer Ingelheim | 1 | $24 |
| Millicent US Inc | 1 | $22 |
| Terumo BCT, Inc. | 1 | $21 |
| Axsome Therapeutics, Inc. | 1 | $21 |
| Acadia Pharmaceuticals Inc | 1 | $19 |
| Shield Therapeutics Inc | 1 | $18 |
| Medline Industries LP | 1 | $15 |
How this compares
$5,131 in reported general payments places this provider in the 90th percentile of 13,581 internal medicine providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 159 | $210,794 |
| EliquisApixaban | 60 | $79,807 |
| JardianceEmpagliflozin | 58 | $68,442 |
| FarxigaDapagliflozin Propanediol | 41 | $51,456 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 27 | $28,857 |
| MyrbetriqMirabegron | 27 | $26,706 |
| MounjaroTirzepatide | 15 | $19,717 |
| LinzessLinaclotide | 14 | $14,249 |
| Advair HfaFluticasone Propion/Salmeterol | 22 | $10,129 |
| Estradiol | 85 | $5,973 |
| Potassium Chloride | 24 | $3,702 |
| Levothyroxine Sodium | 307 | $3,699 |
| Rosuvastatin Calcium | 226 | $3,263 |
| Estradiol (Twice Weekly)Estradiol | 26 | $3,003 |
| Duloxetine Hcl | 69 | $2,934 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $398 | $210,794159 claims |
| PfizerEliquis | $371 | $79,80760 claims |
| Boehringer IngelheimJardiance | $24 | $68,44258 claims |
| AstraZenecaFarxiga | $1,140 | $51,45641 claims |
| GSKTrelegy Ellipta | $313 | $28,85727 claims |
| Astellas Pharma US IncMyrbetriq | $113 | $26,70627 claims |
| Lilly USA, LLCMounjaro | $712 | $19,71715 claims |
| AbbVieLinzess, Synthroid | $398 | $14,87836 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 13,581 internal medicine providers in California.
Other internal medicine in la Jolla
- Rohit Loombala Jolla$15.1M
- Thomas Kippsla Jolla$4.8M
- Andrew ChengSouth San Francisco$55.1M
- Joel NeutelTustin$34.9M
- Donald BrandonSan Diego$34M
- William TownerLos Angeles$27.4M
- Rahul AggarwalSan Francisco$24M
- Masoud AzizadNorthridge$21.1M
- Helen StaceyWalnut Creek$20.4M
- Zeid KayaliColton$14.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.